Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AffyImmune Therapeutics

Request full access

Biopharmaceutical company developing genetically engineered immune cells to fight cancer

Natick, United StatesFounded 2016Biotech & Life Sciences

About AffyImmune Therapeutics

AffyImmune Therapeutics is a biotechnology company focused on advancing cancer immunotherapy by developing proprietary CAR T cell therapies specifically designed to target and destroy solid tumors. The company operates in the oncology market, serving patients with various types of solid tumors. Its business model revolves around the research, development, and commercialization of these advanced therapies. AffyImmune generates revenue through partnerships, licensing agreements, and potentially through direct sales of its therapies upon regulatory approval. The company’s core technology fine-tunes the affinity of CAR T cells to selectively kill tumor cells while sparing healthy cells, thereby reducing toxicity and enhancing the efficacy and longevity of the treatment. Additionally, their engineered CAR T cells can be monitored in real-time during patient treatment, providing valuable data on distribution and activity. AffyImmune's leadership team brings extensive experience in biotechnology and drug development, driven by a commitment to creating life-saving, patient-centric treatments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
61.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Oct 2021 $10M $40M ORI Capital —
EARLY VCEquity / VC Aug 2018 $1M $4M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

AffyImmune Therapeutics website traffic

Latest recorded traffic for AffyImmune Therapeutics is 690 monthly website visits, down 42.5% over the last three months. AffyImmune Therapeutics's team grew 0% over the past year.

Latest monthly visits690 3-month web change-42.5% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AffyImmune Therapeutics in the Natick ecosystem

Live from Dealroom

The AffyImmune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • ORI Capital

Other known investors2 additional known investors

  • Cornell Tech
  • Cornell University
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States88.9%
🇭🇰 Hong Kong11.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AffyImmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AffyImmune Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.